Stempoint Capital LP

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Stempoint Capital LP reported 50 stock positions worth $333.4 million. Its top holding was Syndax Pharmaceuticals (SNDX) at 10.0% of the portfolio, followed by Roivant Sciences (ROIV, 9.6%) and Merus (MRUS, 6.3%). Compared with Q2 2024, it opened 21 new positions, sold out of 13, added to 10 and reduced 17. The biggest buy was a new position in Bristol-Myers Squibb (BMY) and the biggest sale Crinetics Pharmaceuticals (CRNX, shares −61%).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0001952142
Portfolio Value
$333.4M (Q3 2024)
SEC Filing
0001420506-24-002386 ↗ filed Nov 13, 2024

Holdings Value

0$200.0M$400.0M$600.0M Q1 2024: $374.3M Q1 2024 Q2 2024: $339.9M Q2 2024 Q3 2024: $333.4M $333.4M Q3 2024 Q4 2024: $398.7M Q4 2024 Q1 2025: $313.1M Q1 2025 Q2 2025: $310.6M Q2 2025 Q3 2025: $495.9M Q3 2025 Q4 2025: $582.7M Q4 2025 Q1 2026: $520.3M Q1 2026 Q2 2026: $577.9M Q2 2026

Holdings 50 stocks · $333.4M
SNDX Syndax Pharmaceuticals Inc. 9.99% 1,731,191 $33.3M Add +22.6%
ROIV Roivant Sciences Ltd. 9.59% 2,769,819 $32.0M Add +2.1%
MRUS Merus NV 6.31% 421,222 $21.0M Add +45.9%
IMVT Immunovant Inc. 5.74% 671,001 $19.1M Reduce -33.7%
ARQT Arcutis Biotherapeutics Inc. 4.96% 1,778,318 $16.5M Add +84.2%
FOLD Amicus Therapeutics Inc. 4.75% 1,481,809 $15.8M Reduce -0.9%
BMY Bristol-Myers Squibb Co. 4.27% 275,303 $14.2M New
APLT Applied Therapeutics Inc. 3.96% 1,554,586 $13.2M Reduce -29.7%
CRNX Crinetics Pharmaceuticals Inc. 3.28% 213,815 $10.9M Reduce -61.2%
BHVN Biohaven Ltd. 3.24% 216,440 $10.8M Reduce -7.2%
PRAX Praxis Precision Medicines I 3.00% 174,034 $10.0M Add +494.8%
AUTL Autolus Therapeutics PLC 2.85% 2,616,602 $9.5M Reduce -1.7%
INCY Incyte Corp. 2.57% 129,490 $8.6M New
DNLI Denali Therapeutics Inc. 2.46% 282,050 $8.2M Add +12.4%
DAWN Day One Biopharmaceuticals I 2.12% 506,978 $7.1M New
SLRN Acelyrin Inc. 1.95% 1,317,854 $6.5M New
SLNO Soleno Therapeutics Inc. 1.87% 123,177 $6.2M New
CABA Cabaletta Bio Inc. 1.81% 1,278,444 $6.0M Add +8.5%
IMTX Immatics NV 1.54% 449,735 $5.1M Reduce -10.4%
KROS Keros Therapeutics Inc. 1.51% 86,930 $5.0M New
ACLX Arcellx Inc. 1.50% 60,076 $5.0M Reduce -78.6%
VTGN Vistagen Therapeutics Inc. 1.47% 1,846,792 $4.9M Reduce -0.1%
NRIX Nurix Therapeutics Inc. 1.37% 203,015 $4.6M Reduce -0.1%
TCRX Tscan Therapeutics Inc. 1.29% 860,951 $4.3M Add +1.9%
ZURA Zura Bio Ltd. 1.27% 1,044,168 $4.2M New
IDYA Ideaya Biosciences Inc. 1.26% 132,703 $4.2M Add +30.4%
TERN Terns Pharmaceuticals Inc. 1.12% 449,321 $3.7M New
CATX Perspective Therapeutics Inc. 0.95% 238,084 $3.2M Reduce -30.8%
PYXS Pyxis Oncology Inc. 0.94% 850,210 $3.1M Reduce -29.3%
NGNE Neurogene Inc. 0.92% 73,299 $3.1M Reduce -6.8%
URGN Urogen Pharma Ltd. 0.92% 241,984 $3.1M New
VIGL Vigil Neuroscience Inc. 0.76% 743,719 $2.5M Reduce -0.1%
WVE Wave Life Sciences Ltd. 0.74% 300,000 $2.5M New
BBIO Bridgebio Pharma Inc. 0.72% 94,885 $2.4M New
JANX Janux Therapeutics Inc. 0.67% 49,415 $2.2M Reduce -46.8%
SRZN Surrozen Inc. 0.66% 182,918 $2.2M Add +27.5%
RYTM Rhythm Pharmaceuticals Inc. 0.65% 41,268 $2.2M New
BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II 0.63% 200,000 $2.1M No change
SRPT Sarepta Therapeutics Inc. 0.56% 15,014 $1.9M New
TARA Protara Therapeutic Inc. 0.52% 942,857 $1.7M Reduce -4.2%
FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR 0.45% 150,000 $1.5M No change
TRML Tourmaline Bio Inc. 0.43% 55,523 $1.4M New
CAPR Capricor Therapeutics Inc. 0.43% 93,638 $1.4M New
ALKS Alkermes PLC 0.41% 48,918 $1.4M New
CNTA Centessa Pharmaceuticals Ltd. 0.40% 83,662 $1.3M New
MBX MBX Biosciences Inc. 0.39% 50,000 $1.3M New
CYTK Cytokinetics Inc. 0.23% 14,464 $764K New
RVMD Revolution Medicines Inc. 0.23% 16,654 $755K New
ATXS Astria Therapeutics Inc. 0.19% 56,287 $619K New
EWTX Edgewise Therapeutics Inc. 0.16% 19,900 $531K Reduce -92.7%

Options reported separately and not counted above: SNDX calls ($382K), IMVT calls ($113K), APLT calls ($75K), ARQT calls ($13K).

Portfolio Sells Q2 2024 → Q3 2024
CRNX Crinetics Pharmaceuticals Inc. Reduce -61.2% 3.28% −3.98
IMCR Immunocore Holdings PLC-ADR Sold out 0.00% −3.38
ACLX Arcellx Inc. Reduce -78.6% 1.50% −3.05
MRK Merck & Co. Inc. Sold out 0.00% −2.99
GSK GSK PLC-Spon ADR Sold out 0.00% −2.79
KALV Kalvista Pharmaceuticals Inc. Sold out 0.00% −2.55
IMVT Immunovant Inc. Reduce -33.7% 5.74% −2.12
INSM Insmed Inc. Sold out 0.00% −1.71
CLDX Celldex Therapeutics Inc. Sold out 0.00% −1.57
LRMR Larimar Therapeutics Inc. Sold out 0.00% −1.50
CRBP Corbus Pharmaceuticals Holdi Sold out 0.00% −1.35
EWTX Edgewise Therapeutics Inc. Reduce -92.7% 0.16% −1.28
FULC Fulcrum Therapeutics Inc. Sold out 0.00% −1.27
SYRE Spyre Therapeutics Inc. Sold out 0.00% −1.04
JSPR Jasper Therapeutics Inc. Sold out 0.00% −0.96
BDTX Black Diamond Therapeutics I Sold out 0.00% −0.92
SLN Silence Therapeutics PLC-ADR Sold out 0.00% −0.70
JANX Janux Therapeutics Inc. Reduce -46.8% 0.67% −0.47
VTGN Vistagen Therapeutics Inc. Reduce -0.1% 1.47% −0.25
PYXS Pyxis Oncology Inc. Reduce -29.3% 0.94% −0.24
IMTX Immatics NV Reduce -10.4% 1.54% −0.18
VIGL Vigil Neuroscience Inc. Reduce -0.1% 0.76% −0.12
TARA Protara Therapeutic Inc. Reduce -4.2% 0.52% −0.08
CATX Perspective Therapeutics Inc. Reduce -30.8% 0.95% −0.06
NGNE Neurogene Inc. Reduce -6.8% 0.92% +0.08
NRIX Nurix Therapeutics Inc. Reduce -0.1% 1.37% +0.12
AUTL Autolus Therapeutics PLC Reduce -1.7% 2.85% +0.12
FOLD Amicus Therapeutics Inc. Reduce -0.9% 4.75% +0.38
BHVN Biohaven Ltd. Reduce -7.2% 3.24% +0.86
APLT Applied Therapeutics Inc. Reduce -29.7% 3.96% +0.93

Portfolio Buys Q2 2024 → Q3 2024
BMY Bristol-Myers Squibb Co. New 4.27% +4.27
PRAX Praxis Precision Medicines I Add +494.8% 3.00% +2.65
INCY Incyte Corp. New 2.57% +2.57
ARQT Arcutis Biotherapeutics Inc. Add +84.2% 4.96% +2.32
DAWN Day One Biopharmaceuticals I New 2.12% +2.12
SLRN Acelyrin Inc. New 1.95% +1.95
SLNO Soleno Therapeutics Inc. New 1.87% +1.87
KROS Keros Therapeutics Inc. New 1.51% +1.51
SNDX Syndax Pharmaceuticals Inc. Add +22.6% 9.99% +1.47
MRUS Merus NV Add +45.9% 6.31% +1.29
ZURA Zura Bio Ltd. New 1.27% +1.27
ROIV Roivant Sciences Ltd. Add +2.1% 9.59% +1.15
TERN Terns Pharmaceuticals Inc. New 1.12% +1.12
URGN Urogen Pharma Ltd. New 0.92% +0.92
DNLI Denali Therapeutics Inc. Add +12.4% 2.46% +0.75
WVE Wave Life Sciences Ltd. New 0.74% +0.74
BBIO Bridgebio Pharma Inc. New 0.72% +0.72
RYTM Rhythm Pharmaceuticals Inc. New 0.65% +0.65
SRPT Sarepta Therapeutics Inc. New 0.56% +0.56
TRML Tourmaline Bio Inc. New 0.43% +0.43
CAPR Capricor Therapeutics Inc. New 0.43% +0.43
ALKS Alkermes PLC New 0.41% +0.41
CNTA Centessa Pharmaceuticals Ltd. New 0.40% +0.40
MBX MBX Biosciences Inc. New 0.39% +0.39
CYTK Cytokinetics Inc. New 0.23% +0.23
RVMD Revolution Medicines Inc. New 0.23% +0.23
IDYA Ideaya Biosciences Inc. Add +30.4% 1.26% +0.21
SRZN Surrozen Inc. Add +27.5% 0.66% +0.19
ATXS Astria Therapeutics Inc. New 0.19% +0.19
TCRX Tscan Therapeutics Inc. Add +1.9% 1.29% −0.17
CABA Cabaletta Bio Inc. Add +8.5% 1.81% −0.78

Options Activity Q2 2024 → Q3 2024
SNDX Syndax Pharmaceuticals Inc. call New 230,000 $382K
IMVT Immunovant Inc. call New 200,000 $113K
APLT Applied Therapeutics Inc. call New 251,600 $75K
ARQT Arcutis Biotherapeutics Inc. call Reduce -50.0% 250,000 $13K

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 73$577.9MTNGX, ABVX, RVMD, ERAS, TYRA
Q1 2026Amended 70$520.3MSRRK, ABVX, SNDX, RVMD, IMVT
Q4 2025 75$582.7MABVX, SRRK, CNTA, SNDX, GPCR
Q3 2025 76$495.9MROIV, QURE, SRRK, IMVT, DNLI
Q2 2025 50$310.6MSNDX, IMVT, SRRK, CNTA, MDGL
Q1 2025 52$313.1MROIV, SNDX, SRRK, ACLX, MRUS
Q4 2024 48$398.7MSNDX, ROIV, IMVT, MRUS, CRNX
Q3 2024 50$333.4MSNDX, ROIV, MRUS, IMVT, ARQT
Q2 2024Amended 42$339.9MSNDX, ROIV, IMVT, CRNX, MRUS
Q1 2024Amended 45$374.3MROIV, CRNX, SNDX, ARQT, IMVT